Delayed Acyclovir Therapy and Death Among Neonates With Herpes Simplex Virus Infection

AUTHORS: Samir S. Shah, MD, MSCE,^{a,b,c,d,e,f,j} Paul L. Aronson, MD,^{d,g} Zeinab Mohamad, MS,^{g,h} and Scott A. Lorch, MD, MSCE^{d,e,f,h,i}

Divisions of ^aInfectious Diseases, ^bGeneral Pediatrics, ^cEmergency Medicine, and ^dNeonatology, ^eCenter for Pediatric Clinical Effectiveness, and ^fCenter for Outcomes Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; and Departments of ^gPediatrics and ^hBiostatistics and Epidemiology and ⁱCenter for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and ^jDivision of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

KEY WORDS

herpes simplex virus, neonate, acyclovir, therapy

ABBREVIATIONS

CI—confidence interval

CSF—cerebrospinal fluid

HSV—herpes simplex virus

ICD-9—International Classification of Diseases, Ninth Revision

IQR—interquartile range

OR—odds ratio

PHIS—Pediatric Health Information System

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Robert Wood Johnson Foundation.

www.pediatrics.org/cgi/doi/10.1542/peds.2011-0177

doi:10.1542/peds.2011-0177

Accepted for publication Aug 19, 2011

Address correspondence to Samir S. Shah, MD, MSCE, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, ML 7035, Cincinnati, OH 45229. E-mail: ssamir.shah@cchmc.org

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2011 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

Funded by the National Institutes of Health (NIH).

WHAT'S KNOWN ON THIS SUBJECT: Neonatal herpes simplex virus (HSV) infection, although uncommon, is associated with significant mortality and neurologic morbidity. Acyclovir therapy reduces mortality rates. The association between the timing of acyclovir treatment initiation and mortality is not known.

WHAT THIS STUDY ADDS: In this multicenter observational study of neonates with HSV infection, delayed initiation of acyclovir therapy was associated with in-hospital death. Our data support the use of empiric acyclovir therapy for neonates undergoing testing for HSV infection.

abstract

OBJECTIVE: To determine the association of delayed acyclovir therapy with death among neonates with herpes simplex virus (HSV) infection.

METHODS: A multicenter, retrospective, cohort study was conducted between January 1, 2003, and December 31, 2009, with 1086 neonates (age: ≤ 28 days) with HSV infection from 41 tertiary care children's hospitals. Early acyclovir therapy was defined as initiation of intravenous acyclovir treatment within 1 day after hospital admission, and delayed acyclovir therapy was defined as initiation of treatment > 1 and ≤ 7 days after hospital admission. Multivariate logistic regression models determined the association between delayed acyclovir therapy and death, with the use of propensity scores for each neonate's likelihood of receiving delayed acyclovir treatment to control for differences in illness severity between groups.

RESULTS: The median age was 10 days. Delayed acyclovir therapy was administered to 262 neonates (24.1%). In most cases (86.2%) of delayed receipt, acyclovir administration occurred on the second or third day of hospitalization. The overall mortality rate was 7.3% (95% confidence interval: 5.8%–9.0%); 9.5% of those who received delayed acyclovir treatment and 6.6% of those who received early acyclovir treatment died. In a multivariate analysis, delayed acyclovir therapy was associated with significantly greater odds of death (adjusted odds ratio: 2.63 [95% confidence interval: 1.36–5.08]) compared with early acyclovir therapy.

CONCLUSIONS: In this multicenter observational study of neonates with HSV infection, delayed initiation of acyclovir therapy was associated with in-hospital death. Our data support the use of empiric acyclovir therapy for neonates undergoing testing for HSV infection. *Pediatrics* 2011;128:1153–1160

Herpes simplex virus (HSV) infection, although uncommon among neonates,^{1,2} causes significant deaths and neurologic morbidity.^{3,4} Early diagnosis on the basis of clinical examination findings is challenging, because initial symptoms (such as fever or hypothermia) are nonspecific and skin vesicles, which represent the most common overt manifestation of neonatal HSV, are absent for up to 40% of neonates with disseminated or central nervous system disease.^{4,5}

HSV polymerase chain reaction tests, which allow for accurate diagnosis, are widely available.⁶⁻⁸ Therefore, HSV testing is commonly performed for neonates undergoing evaluation with lumbar puncture.^{1,9} Intravenously administered acyclovir improves outcomes,¹⁰ and administration often is initiated at the time of HSV testing. However, most neonates in whom testing is performed do not have HSV.^{1,2,9} In addition, HSV testing is associated with increased hospital length of stay⁹ and the accompanying risks of hospitalization, including medication errors and health care-acquired infections. Empiric acyclovir therapy is costly⁹ and exposes neonates to potential adverse effects such as neutropenia and renal toxicity.¹⁰ As a consequence, there is controversy regarding which neonates would benefit from empiric acyclovir treatment.^{11,12} Should all neonates for whom HSV testing is performed receive empiric acyclovir treatment, or should empiric treatment be reserved for a high-risk subset of patients, such as those with hypotension or disordered coagulation, whose illness severity at presentation has been associated with worse outcomes?^{24,13}

The relationship between delayed initiation of acyclovir therapy and outcomes is not known. Previous studies on this topic used historical comparison groups, were conducted before

the advent of HSV polymerase chain reaction testing, and were not designed specifically to study the association of early versus late initiation of acyclovir treatment for infants with diagnosed HSV. The objective of this study was to determine whether delayed acyclovir therapy was associated with death among neonates with HSV.

METHODS

Data Source

Data for this multicenter, retrospective, cohort study were obtained from the Pediatric Health Information System (PHIS), a national database containing resource utilization data from 41 freestanding, tertiary care, children's hospitals. These hospitals are affiliated with the Child Health Corporation of America (Shawnee Mission, KS), a business alliance of children's hospitals. Participating hospitals provide discharge data, including demographic data, diagnoses, and procedures. Billing data detail drugs, radiologic imaging studies, and laboratory tests charged to each patient. Systematic monitoring occurs on an ongoing basis to ensure data quality, as described previously.^{14,15} The protocol for the performance of this study was reviewed and approved by the Children's Hospital of Philadelphia committees for the protection of human subjects; informed-consent requirements were waived.

Patients

Children aged 28 days or younger with HSV infection were eligible for this study if they were discharged from any of the 41 participating hospitals between January 1, 2003, and December 31, 2009. Patients were considered to have HSV if they received intravenous acyclovir therapy during their hospitalization and were assigned a diagnosis of HSV, as indicated by *International Classification of Diseases, Ninth*

Revision (ICD-9), discharge diagnosis code 054.xx (HSV, with the last 2 digits representing any combination of 1- or 2-digit codes) in any discharge diagnosis field. Patients who received their first dose of intravenous acyclovir treatment >7 days after admission were excluded, because it is likely that such infants were admitted initially with conditions unrelated to HSV. Inborn neonates were excluded.

Study Definitions

Subjects with isolated skin, eye, and mouth disease were identified by the presence of ICD-9 code 054.9 (HSV without mention of complications) in the absence of concomitant codes indicating a HSV-associated complication (ie, meningitis or sepsis). Congenital anomalies, grouped according to involved organ system, included cardiac, neurologic, pulmonary, gastrointestinal, and genitourinary anomalies (Appendix). Receipt of mechanical ventilation and medication usage, except for acyclovir therapy, were included only if they occurred on the first day of hospital admission. Medications included blood products, anticonvulsants, vasoactive agent infusions, and acyclovir. Early acyclovir receipt was defined as receipt of intravenously administered acyclovir on the first day of hospitalization (measured by day from midnight to midnight). Delayed acyclovir receipt was defined as receipt of intravenously administered acyclovir >1 and ≤7 days after admission.

Measured Outcomes

The primary outcome measure was death before hospital discharge.

Measured Exposures

The primary exposure of interest was delayed receipt of intravenously administered acyclovir, because the clinical dilemma typically centers on whether acyclovir should be used empirically.

Statistical Analyses

Categorical variables were described by using frequencies and proportions, whereas continuous variables were described by using mean, median, range, and interquartile range (IQR) values. In unadjusted analyses, patient characteristics and clinical outcomes of early and delayed acyclovir receipt were compared by using χ^2 tests or Fisher's exact tests for categorical variables and Wilcoxon rank-sum tests for continuous variables.

Propensity scores for delayed receipt of acyclovir were constructed to estimate the probability of delayed acyclovir receipt given an observed set of baseline confounders.^{16–18} Propensity scores for delayed receipt of acyclovir allow for more-valid estimates of treatment effects, because the models compare patients with similar likelihoods of receiving delayed acyclovir treatment. Variables used to develop the propensity scores included age, gender, race, hospital, month of admission, and year of admission; use of HSV skin testing and an ICD-9 code for HSV without mention of complications, to account for skin disease as a presenting complaint for HSV; and the need for endotracheal intubation, anticonvulsant therapy, vasoactive agent infusions, and blood product transfusions on the first day of hospital admission, to account for severe illness presentation as a reason for receiving acyclovir. The propensity model's calculated *c* statistic was 0.75.

Multivariate logistic regression analysis was performed to evaluate outcomes associated independently with delayed acyclovir receipt, with adjustment for both propensity scores for delayed receipt of acyclovir and individual covariates.^{19,20} Because disseminated disease is more common among younger infants, we performed a secondary analysis after stratifica-

tion according to age, to identify important subgroup effects.

Additional analyses were conducted to address the residual biases inherent in any multicenter observational study; these biases include residual patient-level confounding, hospital-level confounding, and misclassification bias. First, we repeated the analysis while excluding patients with HSV without complications. Second, we examined the association of the timing of acyclovir treatment initiation (by day) with death by using logistic regression to adjust for residual patient-level confounding. If the association of delayed acyclovir therapy and death resulted from a delay in the initiation of appropriate therapy rather than unmeasured differences in illness severity for patients who received delayed versus early acyclovir therapy, then we should detect a time-dependent relationship between the length of delay and mortality rates. Third, we performed conditional logistic regression analysis with adjustment for delayed acyclovir propensity scores and individual covariates and stratification according to hospital, to adjust for hospital-level confounding.

Finally, only tertiary care children's hospitals participated. Some neonates might have had lumbar punctures performed at other hospitals before transfer to these tertiary care facilities. Patients who received delayed acyclovir treatment would be misclassified as receiving early acyclovir treatment if transfer occurred >24 hours after lumbar puncture and acyclovir treatment was not initiated until arrival at the PHIS hospital. To account for this possibility, we performed a subanalysis restricted to neonates with a hospital charge for cerebrospinal fluid (CSF) testing (culture, cell count, or glucose or protein measurement) within 7 days after hospitalization. This analysis would minimize mis-

classification bias by ensuring that the diagnostic lumbar puncture was performed (and, by inference, the diagnosis of HSV was made) at the PHIS hospital, rather than at the transferring hospital.

All analyses were clustered according to hospital. Two-tailed *P* values of <.05 were considered statistically significant. Because 262 (24.1%) of 1086 neonates with HSV received delayed acyclovir treatment, we had 80% power ($\alpha = .05$) to detect an odds ratio (OR) of ≥ 1.8 for death for patients who received delayed acyclovir treatment, compared with patients who received early acyclovir treatment.

RESULTS

Patient Characteristics

During the study period, 1098 neonates with a discharge diagnosis of HSV received intravenous acyclovir treatment; 12 (1.1%) of those neonates received acyclovir >7 days after hospitalization and thus were excluded. The remaining 1086 neonates were included in this study. There was a median of 25 neonates per hospital (IQR: 18–36 neonates per hospital). Demographic characteristics of patients are presented in Table 1. The median patient age at admission was 10 days (IQR: 6–17 days). One hundred ninety-two patients (17.7%) had an ICD-9 code for HSV without complications, 35 of whom received delayed acyclovir treatment.

Timing of Acyclovir Treatment Initiation

Overall, 262 (24.1%) of 1086 neonates had delayed receipt of acyclovir. In most cases (86.2%) of delayed receipt, acyclovir administration occurred on the second or third day of hospitalization. There was no association between delayed acyclovir administration and the month of admission (χ^2 test, *P* = .505). There was variation

TABLE 1 Characteristics of Patients

Characteristic	n (%)			P
	Overall	Delayed Acyclovir Therapy (N = 262)	Early Acyclovir Therapy (N = 824)	
Age category				.566
0–7 d	354 (32.6)	93 (35.5)	261 (31.7)	
8–14 d	382 (35.2)	91 (34.7)	291 (35.3)	
15–21 d	226 (20.8)	53 (20.2)	173 (21.0)	
22–28 d	124 (11.4)	25 (9.5)	99 (12.0)	
Male	585 (53.9)	139 (53.0)	446 (54.1)	.762
Race/ethnicity ^a				.030
Non-Hispanic white	524 (48.3)	136 (51.9)	388 (47.1)	
Non-Hispanic black	216 (19.9)	47 (17.9)	169 (20.5)	
Hispanic	142 (13.1)	43 (16.4)	99 (12.0)	
Other	128 (11.8)	19 (7.3)	109 (13.2)	
Missing data	76 (7.0)	17 (6.5)	59 (7.2)	
Congenital anomaly	142 (13.1)	45 (17.2)	97 (11.8)	.024
Government payer	635 (58.5)	168 (64.1)	467 (56.7)	.033
HSV without complications	192 (17.7)	35 (13.4)	157 (19.1)	.035
Initial management				
Skin testing for HSV	251 (23.1)	43 (16.4)	208 (25.2)	.003
Vasoactive agent infusions ^b	61 (5.6)	11 (4.2)	50 (6.1)	.252
Anticonvulsant therapy ^c	133 (12.3)	19 (7.3)	114 (13.8)	.005
Blood product transfusion ^d	566 (6.1)	8 (3.0)	36 (4.4)	.347
Endotracheal intubation	74 (6.8)	19 (7.3)	55 (6.7)	.747

Because of rounding, proportions may not total 100.

^a Race/ethnicity data were reported by parents or legal guardians of the subjects. Other races included Asian, Native American, and other. Race was classified as missing data if race was not reported in the database.

^b Vasoactive agent infusions included dobutamine, dopamine, epinephrine, and norepinephrine infusions.

^c Anticonvulsants included diazepam, lorazepam, fosphenytoin, phenytoin, pentobarbital, phenobarbital, and valproate.

^d Blood product transfusions included administration of packed red blood cells, cryoprecipitate, fresh frozen plasma, or platelets.

across hospitals, however. The median proportion of neonates with delayed acyclovir receipt at any hospital was 23.8%, and values ranged from 1.9% to 76.9% (IQR: 15.4%–31.5%).

Outcome Measures

The overall mortality rate was 7.3% (95% confidence interval [CI]: 5.8%–9.0%); mortality rates were 9.5% (95% CI: 6.3%–13.82%) for those with delayed acyclovir receipt and 6.6% (95% CI: 5.0%–8.5%) for those with early

acyclovir receipt (Table 2). With stratification according to age, the mortality rate was highest among neonates aged 7 days or younger, and deaths occurred disproportionately among those with delayed acyclovir receipt (Table 2). Overall, the cumulative mortality rates were 4.4% at 7 days and 6.8% at 28 days after admission. The cumulative mortality rates 7 days after admission were 4.6% for those with delayed acyclovir receipt and 4.4% for those with early acyclovir receipt. The

cumulative mortality rates 28 days after admission were 8.8% for those with delayed acyclovir receipt and 6.2% for those with early acyclovir receipt.

In unadjusted analyses, receipt of vasoactive agent infusions, anticonvulsant therapy, blood product transfusions, and endotracheal intubation on the first day of hospital admission were associated with death; however, delayed acyclovir receipt was not (Table 3). In the multivariate analysis, delayed acyclovir receipt was associated with greater than twofold higher odds of death (Table 4). In the stratified analysis, delayed acyclovir receipt was associated with higher odds of death among neonates aged 14 days or younger (adjusted OR: 3.2 [95% CI: 1.5–7.0]; $P = .003$).

Several additional analyses were performed to address residual patient-level confounding, hospital-level confounding, and potential misclassification of exposure. First, the association of delayed acyclovir therapy and death remained significant when patients with HSV without complications were excluded from the analysis (adjusted OR: 2.55 [95% CI: 1.32–4.93]; $P = .005$). Second, the odds of death increased with each additional day of delay in acyclovir treatment initiation; the mortality rates according to the day of acyclovir treatment initiation were 6.6% for day 1, 8.3% for day 2, 8.8% for day 3, and 16.7% for days 4 to 7 (P for trend = .027). This time-dependent relationship remained significant in an adjusted analysis stratified according to the day of acyclovir treatment initiation (Fig 1). Third, delayed acyclovir treatment remained associated with death when the analysis was stratified according to hospital by using conditional logistic regression (adjusted OR: 2.92 [95% CI: 1.51–5.64]; $P = .001$). Finally, on-site CSF studies were performed for 437 (40.2%) of 1086 neonates; 20 (4.6%) of those infants died,

TABLE 2 In-Hospital Deaths Among Neonates With HSV Infection According to Age and Timing of Acyclovir Receipt

	n/N (%)		
	Overall	Delayed Acyclovir Therapy	Early Acyclovir Therapy
Overall	79/1086 (7.3)	25/262 (9.5)	54/824 (6.6)
Age category			
0–7 d	38/354 (10.7)	15/93 (16.1)	23/261 (8.8)
8–14 d	32/382 (8.4)	9/91 (9.9)	23/291 (7.9)
15–21 d	8/226 (3.5)	1/53 (1.9)	7/173 (4.1)
22–28 d	1/124 (0.8)	0/25 (0)	1/99 (1.0)

TABLE 3 Univariate Analyses of Risk Factors for Death Among Neonates With HSV Infection

Characteristic	Unadjusted OR (95% CI)	P
Age category ^a		
0–7 d	Reference	
8–14 d	0.76 (0.46–1.25)	.277
15–21 d	0.31 (0.14–0.67)	.003
22–28 d	0.07 (0.01–0.50)	.008
Male	0.98 (0.62–1.55)	.917
Race		
Non-Hispanic white	Reference	
Non-Hispanic black	1.06 (0.59–1.92)	.842
Hispanic	0.64 (0.28–1.47)	.298
Other	1.41 (0.73–2.72)	.312
Congenital anomaly	2.10 (1.20–3.67)	.009
Government payer	2.37 (1.40–4.03)	.001
HSV without complications	0.58 (0.28–1.18)	.133
Initial management		
Delayed acyclovir therapy	1.50 (0.92–2.47)	.107
Skin testing for HSV	0.51 (0.27–0.99)	.048
Vasoactive agent infusions	27.42 (15.25–49.32)	<.001
Anticonvulsant therapy	2.89 (1.69–4.94)	<.001
Blood product transfusion	25.04 (14.16–44.29)	<.001
Endotracheal intubation	7.70 (4.39–13.49)	<.001

^a Age at hospital admission.

TABLE 4 Multivariate Analysis of Risk Factors for Death Among Neonates With HSV Infection

Variable	Adjusted OR (95% CI) ^a	P
Delayed acyclovir therapy	2.62 (1.34–5.09)	.005
Age category		
0–7 d	Reference	
8–14 d	0.81 (0.42–1.56)	.525
15–21 d	0.37 (0.15–0.95)	.039
22–28 d	0.11 (0.02–0.77)	.027

^a The model also adjusted for propensity scores, year, race/ethnicity, vasoactive agent infusions, anticonvulsant therapy, blood product transfusions, endotracheal intubation, HSV testing of skin lesions, and HSV without complications.

FIGURE 1

Relationship between the timing of acyclovir treatment initiation and the odds of death. The dashed line represents the reference value (early acyclovir initiation). The circles represent adjusted ORs, and the vertical lines represent 95% CIs. The model was adjusted for propensity scores (for trend in adjusted ORs, $P = .003$).

compared with 59 (9.1%) of 649 infants without a charge for CSF studies within 7 days of hospitalization. In a multivariate analysis restricted to the subset of infants with on-site CSF studies, the strength of the association between delayed acyclovir treatment and death was even stronger (adjusted OR: 9.16 [95% CI: 3.41–24.66]; $P < .001$).

DISCUSSION

This multicenter observational study examined the association between delayed administration of acyclovir and death among neonates with HSV. Delayed receipt of acyclovir >1 day after admission was associated with higher in-hospital mortality rates. The association was strongest for neonates aged 14 days or younger, for whom the risk of disseminated infection and consequently the risk of death are greatest. In addition, the response seemed to be time-dependent; each additional day of delay was associated with an even greater mortality rate compared with the previous day.

Neonatal HSV infection is a severe disease with high mortality rates despite intravenous acyclovir therapy.¹⁰ An open-label trial compared different acyclovir dosage regimens among 88 neonates with HSV. The 12-month mortality rates for neonates who received “high-dose” acyclovir (60 mg/kg per day), that is, 31% among neonates with disseminated disease and 6% among neonates with central nervous system disease, were three-fold lower than those observed with the standard dosage regimen (30 mg/kg per day).¹⁰ After publication of that study in 2001, administration of high-dose acyclovir quickly became the standard of care.²¹ However, the mean duration of symptoms before study enrollment was >5 days.¹⁰ This delay from symptom onset to initiation of appropriate therapy presents an additional opportunity to improve clinical outcomes. Earlier initiation of acyclovir therapy for neonates

with HSV might lead to even lower mortality rates by preventing progression to more-severe disease. Progression from isolated cutaneous disease to involvement of other sites occurs within 1 week for approximately three-fourths of untreated infants.^{3,22} Whitley et al⁵ compared the clinical presentation of neonates with HSV during 2 consecutive time periods, 1973–1981 and 1982–1987. The duration of symptoms before therapy decreased from 6.5 days in the first time period to 4.8 days in the second time period, concomitant with a significant decrease in the number of neonates with disseminated disease and an increase in skin, eye, and mouth disease. The authors postulated that earlier diagnosis in the second period (1982–1987) might have identified more skin, eye, and mouth disease before progression to the disseminated form.⁵ It is possible that earlier initiation of acyclovir treatment (even 1–2 days sooner) would halt this progression.

Clinicians must weigh the potential risks of empiric therapy for uninfected neonates against the risks of delaying administration of acyclovir to HSV-infected neonates when earlier therapy is associated with lower mortality rates. Because measures of illness severity (eg, vasoactive agent infusions) also were associated with death, the benefits of early acyclovir therapy might be greater earlier in the course of the illness, before neonates require such therapeutic interventions. Some clinicians argue that empiric acyclovir treatment always should accompany HSV testing, especially for infants aged 21 days or younger¹²; our study supports this approach. It is not clear which neonates should be tested for HSV,²³ and there are many factors that influence clinicians' decision to test.^{1,24} Future studies should attempt to identify the subset of neonates at low risk of HSV, a population that might not re-

quire routine HSV testing and empiric acyclovir treatment.

This multicenter observational study has several limitations. Discharge diagnosis coding might be unreliable for specific diseases. However, we included patients who had a discharge diagnosis of HSV and received treatment with acyclovir, which made it likely that the patients truly had HSV infection. Also, because freestanding children's hospitals often do not have birthing units, our results might not be generalizable to premature infants in birthing units, for whom the risk of HSV infection might be higher.²⁵

In addition, there might be unmeasured confounding or residual confounding according to indication for early versus delayed acyclovir therapy, related to clinical presentation. This effect might influence our results in 2 different ways. First, we would expect that patients who received early acyclovir treatment would be sicker than those who received delayed acyclovir treatment. We included variables associated with greater severity of illness (such as receipt of vasoactive agent infusions) in the propensity score and separately as covariates in multivariate analyses. However, we could not account for clinical or laboratory factors, such as hypothermia or disseminated intravascular coagulation, which also might have influenced the timing of acyclovir administration. It is likely that such findings would lead to early administration of acyclovir and thus bias our results toward finding no difference. Because we found an association between delayed acyclovir therapy and mortality rates, it is possible that earlier initiation of acyclovir treatment would be associated with an even greater benefit than found in our study. Second, we cannot exclude the possibility that the early acyclovir treatment group included a disproportionate number of patients with disease limited to cutaneous or mucosal surfaces at pre-

sentation. Because outcomes are better with skin, eye, and mouth disease, this would have biased our results toward finding a mortality rate difference when none existed. We minimized the impact of such misclassification by including HSV without complications in our propensity score and as a covariate in our multivariate analyses. We also repeated the analysis with the exclusion of patients with HSV without complications. Furthermore, the odds of death increased with each additional day of delay in the initiation of acyclovir treatment. We would not expect such a progressive increase in the odds of death if the mortality rate differences were attributable solely to differences in the type of disease at presentation.

We also could not verify the dose of acyclovir used. After publication of the study by Kimberlin et al¹⁰ in 2001, high-dose acyclovir therapy immediately became the standard of care for neonates with HSV at our institution, as well as at other freestanding children's hospitals. In addition, high-dose acyclovir therapy was recommended by the American Academy of Pediatrics in 2003,²¹ the first year of our study. Therefore, it is unlikely that deaths in this study were the result of suboptimal acyclovir dosing.

Misclassification of the exposure (ie, delayed acyclovir receipt) might have occurred. Exposure is classified according to day (from midnight to midnight) in the PHIS, rather than 24-hour blocks after admission. Therefore, patients who received acyclovir within 24 hours after hospitalization might have been classified as receiving delayed acyclovir treatment. This misclassification would be most important within the first 24 hours, after which days are more important. This misclassification of patients would be expected to bias our results toward finding no difference; therefore, our results might underestimate the mortality rate differ-

ence between patients who received early versus delayed acyclovir treatment. Misclassification of exposure also might have occurred for patients who were transferred from another institution, who would have been classified erroneously as receiving early acyclovir treatment if acyclovir therapy was initiated within 24 hours after transfer to the PHIS-participating hospital but >24 hours after presentation for care. This potential misclassification would have biased our results toward finding no mortality rate differ-

ence. When we limited our analysis to patients with on-site CSF studies, the odds of death with delayed acyclovir treatment were increased. Therefore, the mortality rate for neonates who receive delayed acyclovir therapy might be higher than the rate reported in this study. Finally, other important outcomes, such as neurologic morbidity, could not be measured in this study.

CONCLUSIONS

This multicenter observational study found that delayed initiation of acyclo-

vir therapy was associated with in-hospital death among neonates with HSV infection. Our data support the use of empiric acyclovir therapy for neonates undergoing testing for HSV infection.

ACKNOWLEDGMENTS

Dr Shah received support from National Institute of Allergy and Infectious Diseases grant K01 AI73729 and the Robert Wood Johnson Foundation under its Physician Faculty Scholar Program.

REFERENCES

- Cohen DM, Lorch SA, King RL, Hodinka RL, Cohn KA, Shah SS. Factors influencing the decision to test young infants for herpes simplex virus infection. *Pediatr Infect Dis J*. 2007;26(12):1156–1158
- Caviness AC, Demmler GJ, Almendarez Y, Selwyn BJ. The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates. *J Pediatr*. 2008;153(2):164–169
- Whitley RJ, Nahmias AJ, Soong SJ, Galasso GG, Fleming CL, Alford CA. Vidarabine therapy of neonatal herpes simplex virus infection. *Pediatrics*. 1980;66(4):495–501
- Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. *Pediatrics*. 2001;108(2):223–229
- Whitley RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates. *J Infect Dis*. 1988;158(1):109–116
- Kimura H, Futamura M, Kito H, et al. Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid. *J Infect Dis*. 1991;164(2):289–293
- Troendle-Atkins J, Demmler GJ, Buffone GJ. Rapid diagnosis of herpes simplex virus encephalitis by using the polymerase chain reaction. *J Pediatr*. 1993;123(3):376–380
- Lakeman FD, Whitley RJ. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. *J Infect Dis*. 1995;171(4):857–863
- Shah SS, Volk J, Mohamad Z, Hodinka RL, Zorc JJ. Herpes simplex virus testing and hospital length of stay in neonates and young infants. *J Pediatr*. 2010;156(5):738–743
- Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. *Pediatrics*. 2001;108(2):230–238
- Kimberlin DW. When should you initiate acyclovir therapy in a neonate? *J Pediatr*. 2008;153(2):155–156
- Long SS. In defense of empiric acyclovir therapy in certain neonates. *J Pediatr*. 2008;153(2):157–158
- Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. *N Engl J Med*. 1991;324(7):450–454
- Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. *JAMA*. 2008;299(17):2048–2055
- Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. *Clin Infect Dis*. 2009;49(9):1369–1376
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika*. 1983;70(1):41–55
- Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional mul-
- tivariable methods. *J Clin Epidemiol*. 2006;59(5):437–447
- Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. *Pharmacoepidemiol Drug Saf*. 2004;13(12):841–853
- Imbens GW. Nonparametric estimation of average treatment effects under heterogeneity: a review. *Rev Econ Stat*. 2004;86(1):4–29
- Greenland S. Introduction to regression modeling. In: Rothman KJ, Greenland S, eds. *Modern Epidemiology*. 3rd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008:446–451
- Pickering LK, ed. *Red Book: 2003 Report of the Committee on Infectious Diseases*. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003:344–353
- Whitley RJ, Nahmias AJ, Visintine AM, Fleming CL, Alford CA. The natural history of herpes simplex virus infection of mother and newborn. *Pediatrics*. 1980;66(4):489–494
- Caviness AC, Demmler GJ, Selwyn BJ. Clinical and laboratory features of neonatal herpes simplex virus infection: a case-control study. *Pediatr Infect Dis J*. 2008;27(5):425–430
- Davis KL, Shah SS, Frank G, Eppes SC. Why are young infants tested for herpes simplex virus? *Pediatr Emerg Care*. 2008;24(10):673–678
- O'Riordan DP, Golden WC, Aucott SW. Herpes simplex virus infections in preterm infants. *Pediatrics*. 2006;118(6). Available at: www.pediatrics.org/cgi/content/full/118/6/e1612

APPENDIX ICD-9 Discharge Diagnosis Codes Used to Identify Neonates With Congenital Anomalies

Anomaly Category	ICD-9 Code	Definition
Neurologic anomalies	742	Encephalocele
	742.3	Congenital hydrocephalus
	742.4	Other anomalies of brain
	742.59	Other anomalies of spinal cord
	742.8	Other anomalies of nervous system
	742.9	Unspecified anomaly of brain, spinal cord, and nervous system
Head/neck anomalies	756.1	Anomaly of spine, unspecified
	744.89	Other anomalies of face and neck
	744.9	Unspecified anomalies of face and neck
	748	Choanal atresia
	748.1	Other anomalies of nose
	749	Cleft palate, unspecified
	749.1	Cleft lip, unspecified
	749.24	Bilateral cleft palate with cleft lip, incomplete
	754	Congenital musculoskeletal deformities of skull, face, and jaw
	756	Congenital musculoskeletal anomalies of skull and face bones
Cardiac anomalies	745.1	Complete transposition of great vessels
	745.2	Tetralogy of Fallot
	745.4	Ventricular septal defect
	745.5	Ostium secundum-type atrial septal defect
	745.69	Other endocardial cushion defect
	746.02	Stenosis, congenital
	746.3	Congenital stenosis of aortic valve
	746.6	Congenital mitral insufficiency
	746.83	Infundibular pulmonic stenosis
	746.86	Congenital heart block
	746.87	Malposition of heart and cardiac apex
	746.89	Other anomaly of heart
	746.9	Unspecified anomaly of heart
	747.1	Coarctation of aorta (preductal) (postductal)
	747.3	Anomalies of pulmonary artery
	747.69	Anomalies of other specified sites of peripheral vascular system
	747.9	Unspecified anomaly of circulatory system
Pulmonary anomalies	748.3	Other anomalies of larynx, trachea, and bronchus
	748.5	Agenesis, hypoplasia, and dysplasia of lung
	748.69	Other anomalies of lung
	756.6	Anomalies of diaphragm
Gastrointestinal anomalies	750.5	Congenital hypertrophic pyloric stenosis
	751.1	Atresia and stenosis of small intestine
	751.2	Atresia and stenosis of large intestine, rectum, and anal canal
	751.3	Hirschsprung's disease and other congenital functional disorders of colon
	751.4	Anomalies of intestinal fixation
	751.5	Other anomalies of intestine
	751.6	Unspecified anomaly of gallbladder, bile ducts, and liver
	751.69	Other anomalies of gallbladder, bile ducts, and liver
	756.79	Other congenital anomalies of abdominal wall
	752.7	Indeterminate sex and pseudohermaphroditism
Genitourinary anomalies	752.8	Other specified anomalies of genital organs
	753.15	Renal dysplasia
	753.19	Other specified cystic kidney disease
	753.2	Unspecified obstructive defect of renal pelvis and ureter
	753.29	Other obstructive defects of renal pelvis and ureter
	753.3	Other specified anomalies of kidney
	753.4	Other specified anomalies of ureter
	753.7	Anomalies of urachus
	753.8	Other specified anomalies of bladder and urethra
	753.9	Unspecified anomaly of urinary system
	758.6	Gonadal dysgenesis
Musculoskeletal anomalies	755.59	Other anomalies of upper limb, including shoulder girdle
	756.9	Other and unspecified anomalies of musculoskeletal system
	757.31	Congenital ectodermal dysplasia
Genetic anomalies	758	Down's syndrome
	758.3	Autosomal deletion syndromes
	758.5	Other conditions attributable to autosomal anomalies
	759.3	Situs inversus